Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress
GOTHENBURG, Sweden, September 12, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study (ISO-CC-007) in metastatic colorectal cancer (mCRC) will be presented at the European Society for Medical Oncology (ESMO)Â (https://www.esmo.org/Conferences/ESMO-Congress-2019) 2019 Congress, to be held from September 27 to October 1, 2019, in Barcelona, Spain.
